Blog Archives

Webinar – Use Basophils as Biomarker for Potency and Efficacy of Drugs in Development with Flow CAST®  Inhibitors of PI3K and BTK pathways are a large focus for pharmaceutical companies with several small molecule inhibitors currently at different stages of development. Enzymatic assays to measure the direct activity of compounds are available in the market

BÜHLMANN Laboratories AG is proud to celebrate its 40 Years Anniversary in 2016. A public symposium with the topic “Aging and Biology” will be held on Friday, 8th of April 2016 in honor to the long-lasting and unique success story in developing, manufacturing and selling of diagnostic products. Read more…

Join BÜHLMANN Laboratories AG and BUHLMANN Diagnostics Corp (BDC) Tuesday April 19, 2016 11:00AM EST/ 8:00AM PST/ 5:00PM CET Inhibitors of PI3K and BTK pathways are a large focus for pharmaceutical companies with several small molecule inhibitors currently at different stages of development. Enzymatic assays to measure the direct activity of compounds are available in

We are proud to announce the launch of the new Quantum Blue® Infliximab trough level rapid test. Detection and monitoring of serum levels of the anti-TNFalpha monoclonal antibody is a key element in the treatment of IBD patients and helps to manage dosage of the infliximab therapy. Read more.